Please assess the completion status of the following clinical trial:

Trial Title: Single Ascending Dose Study of PBI-4547 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male participants or non-childbearing potential female participants, ≥18 and ≤55 years.~* Body mass index \> 18.5 and \< 30.0 kg/m\^2, and body weight ≥ 50.0 kg for male participants and ≥ 45.0 kg for female participants.~* Continuous non-smoker who has not used tobacco or nicotine-containing products for at least 3 months prior to screening.~* Male participants with a pregnant partner must agree to use a condom from the first dosing until at least 90 days after study drug administration.~* Male participants must be willing not to donate sperm until 90 days after study drug administration.~Exclusion Criteria:~* Any clinically significant abnormality or abnormal laboratory test results.~* An estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m\^2.~* Positive urine drug screen and history of significant drug abuse.~* History of significant allergic reactions to any drug.~* Use of any drugs known to induce or inhibit hepatic drug metabolism.~* Positive pregnancy test or breast-feeding participant.~* Clinically significant abnormalities in ECG, blood pressure, and heart rate at screening.~* History of significant alcohol abuse or regular use of alcohol.~* Use of medication other than topical products without significant systemic absorption.~* Donation of plasma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1, Dose 1 of PBI-4547 or Placebo (Type: EXPERIMENTAL): Dose 1 of PBI-4547 or matching Placebo tablets by mouth
- Cohort 2, Dose 2 of PBI-4547 or Placebo (Type: EXPERIMENTAL): Dose 2 of PBI-4547 or matching Placebo tablets by mouth
- Cohort 3, Dose 3 of PBI-4547 or Placebo (Type: EXPERIMENTAL): Dose 3 of PBI-4547 or matching Placebo tablets by mouth
- Cohort 4, Dose 4 of PBI-4547 or Placebo (Type: EXPERIMENTAL): Dose 4 of PBI-4547 or matching Placebo tablets by mouth
- Cohort 5, Dose 5 of PBI-4547 or Placebo (Type: EXPERIMENTAL): Dose 5 of PBI-4547 or matching Placebo tablets by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).